drugset / Trial / NCT04052204
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Phase 1/2
Terminated
3 enrolled
Pfizer
Astellas Pharma Inc · collabEMD Serono · collabNektar Therapeutics · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or enzalutamide in metastatic castration resistant prostate cancer (mCRPC).
Timeline
- Start
- 2019-12-30
- Primary completion
- 2020-09-29
- Completion
- 2020-09-29
Outcome
Outcome not reported
Stopped: “Study prematurely terminated as the experimental treatments evaluated in study B9991040 may not provide additional clinical benefit over current or future Standard of Care in the different therapeutic indications that this trial was to evaluate.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | — |
| Subject | Bempegaldesleukin | Protein / enzyme biologic | — | — |
| Subject | Enzalutamide | Other / unclassified | — | — |
| Subject | Talazoparib | Small molecule | — | — |